Primary Membranous Nephropathy clinical trials

Explore recruiting primary membranous nephropathy clinical trials.

Recruiting primary membranous nephropathy studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Primary Membranous Nephropathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2/3, Multicenter, Randomized, Active-Controlled, Open-label Study to Evaluate the Efficacy and Safety of Zanubrutinib in Patients With Primary Membranous Nephropathy

Spain, Poland, Czechia, Italy

Phase II and Phase III (Integrated) EU CTIS Study details

Obinutuzumab for primary membranous nephropathy: a pilot study in patients with rituximab-resistant or rituximab-dependent nephrotic syndrome and in patients intolerant to rituximab (the ORION study)

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Obinutuzumab induced decreases of PLA2Rab in MN: a pilot study

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2b/3 Adaptive, Randomized, Active controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy

Hungary, Ireland, Czechia, Italy, Spain, Germany +1 more

Phase II and Phase III (Integrated) EU CTIS Study details

A Phase III, Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients with Primary Membranous Nephropathy

Poland, Italy, France, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1920 in Adult Participants with PMN (Primary Membranous Nephropathy) who are at a High Risk for Disease Progression (AUTUMN)

Spain, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Primary Membranous Nephropathy trials by city

Primary Membranous Nephropathy in Toronto Primary Membranous Nephropathy in Vancouver Primary Membranous Nephropathy in Montreal Primary Membranous Nephropathy in Calgary Primary Membranous Nephropathy in Edmonton Primary Membranous Nephropathy in Ottawa Primary Membranous Nephropathy in Winnipeg Primary Membranous Nephropathy in Quebec City Primary Membranous Nephropathy in Hamilton Primary Membranous Nephropathy in Kitchener Primary Membranous Nephropathy in London Primary Membranous Nephropathy in Halifax Primary Membranous Nephropathy in New York Primary Membranous Nephropathy in Los Angeles Primary Membranous Nephropathy in Chicago Primary Membranous Nephropathy in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease